During Wednesday's Lightning Round segment of Mad Money one caller asked Jim Cramer about Amarin Corp. (AMRN) : "This is speculative and should only be bought as a spec," he replied about the biopharma company that develops and markets medicines for cardiovascular disease.
More from Investing
The key issue in a better market is to put more money to work and have more exposure.
Outside of the ETF launch which could generate flow into the crypto space, it is important to ask what the real theme is for Bitcoin.
Let's see if this is the time to step on the accelerator.
Despite its rally, Royal Dutch Shell remains attractive thanks to its generous dividend and its expected 5-year total return.